EUVIMEDEUVIMED entdecken
Multizentrische Studie

Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment

Yiming Cheng, Jian Chen, Carlos Vigil, Shahram Khanzadeh, Anita Rampersad, Thomas Prebet, Yan Li

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04797-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Yiming Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Triazines, Aminopyridines, Liver Diseases, Antineoplastic Agents. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazinesAminopyridinesLiver DiseasesAntineoplastic AgentsHumansMaleFemaleMiddle AgedAgedArea Under CurveIsocitrate DehydrogenaseAdultAdministration, OralSeverity of Illness IndexLeukemia, Myeloid, Acute

Stichwörter der Autor:innen

EnasidenibHepatic impairmentPharmacokinetics

Substanzen

TriazinesenasidenibAminopyridinesIsocitrate DehydrogenaseAntineoplastic AgentsIDH2 protein, human

Autor:innen und Institutionen

  • Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA.
  • Hematology Global Drug Development, Bristol Myers Squibb, Giralda Farms, NJ, USA.
  • WorldWide Patient Safety, Bristol Myers Squibb, San Diego, CA, USA.
  • Hematology Clinical Science, Bristol Myers Squibb, Giralda Farms, NJ, USA.
  • Early Clinical Development Hematology and Cell Therapy, Giralda Farms, NJ, USA.
  • Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA. Yan.Li@bms.com.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Cheng, Y., Chen, J., Vigil, C., Khanzadeh, S., Rampersad, A., Prebet, T., & Li, Y. (2025). Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04797-2

Vancouver

Cheng Y, Chen J, Vigil C, Khanzadeh S, Rampersad A, Prebet T, et al. Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04797-2

BibTeX
@article{Cheng2025,
  author = {Cheng, Yiming and Chen, Jian and Vigil, Carlos and Khanzadeh, Shahram and Rampersad, Anita and Prebet, Thomas and Li, Yan},
  title = {Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04797-2}
}
Kostenlos starten →